[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb (BMY) Outperforms Broader Market: What You Need to Know",
    "summary": "Bristol Myers Squibb (BMY) closed at $48.02 in the latest trading session, marking a +2.85% move from the prior day.",
    "url": "https://finnhub.io/api/news?id=b21a2566ac2cc37ada6006282c15ff4e6db322409435cb7c125298ba213c154e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753220702,
      "headline": "Bristol Myers Squibb (BMY) Outperforms Broader Market: What You Need to Know",
      "id": 136038431,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb (BMY) closed at $48.02 in the latest trading session, marking a +2.85% move from the prior day.",
      "url": "https://finnhub.io/api/news?id=b21a2566ac2cc37ada6006282c15ff4e6db322409435cb7c125298ba213c154e"
    }
  },
  {
    "ts": null,
    "headline": "Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock",
    "summary": "Replimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma treatment.",
    "url": "https://finnhub.io/api/news?id=a621e3ed253e0b5c49a3f5d10a43b12acafb6c2cdf811b51032f273bcda81c20",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753205380,
      "headline": "Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock",
      "id": 136033465,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Replimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma treatment.",
      "url": "https://finnhub.io/api/news?id=a621e3ed253e0b5c49a3f5d10a43b12acafb6c2cdf811b51032f273bcda81c20"
    }
  },
  {
    "ts": null,
    "headline": "JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra",
    "summary": "Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque psoriasis.",
    "url": "https://finnhub.io/api/news?id=46ee6b6845a8e85450cb3219d3a28ad1500ca2381313b6df1dc338009ba8806b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753199460,
      "headline": "JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra",
      "id": 136033330,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque psoriasis.",
      "url": "https://finnhub.io/api/news?id=46ee6b6845a8e85450cb3219d3a28ad1500ca2381313b6df1dc338009ba8806b"
    }
  },
  {
    "ts": null,
    "headline": "Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment",
    "summary": "Shares of  Replimune Group  cratered on Tuesday after the biotech said the U.S. Food and Drug Administration rejected an application seeking approval of its experimental skin cancer treatment.  While the FDA didn’t raise any safety issues, the agency indicated it wouldn’t be able to approve the application in its current form, Replimune said.  Shares fell 75% to $3.04, putting the stock on track for a record closing low, according to Dow Jones Market Data.",
    "url": "https://finnhub.io/api/news?id=31bd853fe786c7058225236878a0a472e90765f17b63d54b4bf90d357947582d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753196700,
      "headline": "Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment",
      "id": 136033596,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Shares of  Replimune Group  cratered on Tuesday after the biotech said the U.S. Food and Drug Administration rejected an application seeking approval of its experimental skin cancer treatment.  While the FDA didn’t raise any safety issues, the agency indicated it wouldn’t be able to approve the application in its current form, Replimune said.  Shares fell 75% to $3.04, putting the stock on track for a record closing low, according to Dow Jones Market Data.",
      "url": "https://finnhub.io/api/news?id=31bd853fe786c7058225236878a0a472e90765f17b63d54b4bf90d357947582d"
    }
  },
  {
    "ts": null,
    "headline": "Replimune Shares Plumb All-Time Lows After FDA Rejection",
    "summary": "Replimune Shares Plumb All-Time Lows After FDA Rejection",
    "url": "https://finnhub.io/api/news?id=9f1a796e12ee6a693579ca02a1b1a25be33ac1284e35f8c6bc32203b08a65011",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753177380,
      "headline": "Replimune Shares Plumb All-Time Lows After FDA Rejection",
      "id": 136049837,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Replimune Shares Plumb All-Time Lows After FDA Rejection",
      "url": "https://finnhub.io/api/news?id=9f1a796e12ee6a693579ca02a1b1a25be33ac1284e35f8c6bc32203b08a65011"
    }
  },
  {
    "ts": null,
    "headline": "Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement",
    "summary": "Lyell Immunopharma's LYL314 CAR-T therapy shows durable responses in advanced LBCL patients. Learn about trials and upcoming milestones.",
    "url": "https://finnhub.io/api/news?id=da32dd96dfa28ed33587dc4c3eb3773289637020ef818dadd03198b9854c5153",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753174927,
      "headline": "Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement",
      "id": 136030925,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2212517857/image_2212517857.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Lyell Immunopharma's LYL314 CAR-T therapy shows durable responses in advanced LBCL patients. Learn about trials and upcoming milestones.",
      "url": "https://finnhub.io/api/news?id=da32dd96dfa28ed33587dc4c3eb3773289637020ef818dadd03198b9854c5153"
    }
  },
  {
    "ts": null,
    "headline": "Replimune: FDA Rejects Application Seeking RP1 Approval",
    "summary": "Replimune: FDA Rejects Application Seeking RP1 Approval",
    "url": "https://finnhub.io/api/news?id=a02c86a85f0c61d34c0b8e703f57fac603aa213c4f94055bb950330514f9d06f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753169640,
      "headline": "Replimune: FDA Rejects Application Seeking RP1 Approval",
      "id": 136049838,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Replimune: FDA Rejects Application Seeking RP1 Approval",
      "url": "https://finnhub.io/api/news?id=a02c86a85f0c61d34c0b8e703f57fac603aa213c4f94055bb950330514f9d06f"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q1 Earnings?",
    "summary": "Over the past six months, Bristol-Myers Squibb’s shares (currently trading at $46.80) have posted a disappointing 18% loss, well below the S&P 500’s 3.7% gain. This might have investors contemplating their next move.",
    "url": "https://finnhub.io/api/news?id=08c46ff2f042ac955ea9874666ef916a9c0d8b0a4c5f891335e9451d76cff111",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753157046,
      "headline": "Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q1 Earnings?",
      "id": 136031734,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Over the past six months, Bristol-Myers Squibb’s shares (currently trading at $46.80) have posted a disappointing 18% loss, well below the S&P 500’s 3.7% gain. This might have investors contemplating their next move.",
      "url": "https://finnhub.io/api/news?id=08c46ff2f042ac955ea9874666ef916a9c0d8b0a4c5f891335e9451d76cff111"
    }
  }
]